Last reviewed · How we verify

NCT03261414: HYSTERIA

HYSTERIA Evaluation of Clinical HYpnosis After Surgical Resection for Crohn Disease on Post-operative Analgesia

Completed NA Last updated 9 March 2021
What this trial tests

NA trial testing Hypnosis in Inflammatory Bowel Diseases in 77 participants. Completed in 30 January 2020.

Timeline
27 May 2015
Primary endpoint
30 January 2020
30 January 2020

Quick facts

Lead sponsorUniversity Hospital, Lille
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment77
Start date27 May 2015
Primary completion30 January 2020
Estimated completion30 January 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Lille

Who can join

18 and older, any sex, with Inflammatory Bowel Diseases or Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study will be to show a decrease in postoperative morphine consumption by the practice of perioperative self-hypnosis in patients undergoing laparoscopic ileo-caecal resection for Crohn's disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Psychological interventions for treatment of inflammatory bowel disease.
    Tiles-Sar N, Neuser J, de Sordi D, Baltes A, et al · · 2025 · cited 5× · PMID 40243391 · DOI 10.1002/14651858.cd006913.pub3

Verify or expand the search:

Other trials of Hypnosis

Trials testing the same drug.

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03261414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing